Cargando…

Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067

OBJECTIVES: The aim of this study was to compare the performance of different extrapolation modeling techniques and analyze their impact on structural uncertainties in the economic evaluations of cancer immunotherapy. METHODS: The individual patient data was reconstructed through published Checkmate...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Taihang, Zhao, Mingye, Liang, Leyi, Shi, Lizheng, Tang, Wenxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169997/
https://www.ncbi.nlm.nih.gov/pubmed/36757569
http://dx.doi.org/10.1007/s41669-023-00391-5
_version_ 1785039149620789248
author Shao, Taihang
Zhao, Mingye
Liang, Leyi
Shi, Lizheng
Tang, Wenxi
author_facet Shao, Taihang
Zhao, Mingye
Liang, Leyi
Shi, Lizheng
Tang, Wenxi
author_sort Shao, Taihang
collection PubMed
description OBJECTIVES: The aim of this study was to compare the performance of different extrapolation modeling techniques and analyze their impact on structural uncertainties in the economic evaluations of cancer immunotherapy. METHODS: The individual patient data was reconstructed through published Checkmate 067 Kaplan Meier curves. Standard parametric models and six flexible techniques were tested, including fractional polynomial, restricted cubic splines, Royston–Parmar models, generalized additive models, parametric mixture models, and mixture cure models. Mean square errors (MSE) and bias from raw survival plots were used to test the model fitness and extrapolation performance. Variability of estimated incremental cost-effectiveness ratios (ICERs) from different models was used to inform the structural uncertainty in economic evaluations. All indicators were analyzed and compared under cut-offs of 3 years and 6.5 years, respectively, to further discuss model impact under different data maturity. R Codes for reproducing this study can be found on GitHub. RESULTS: The flexible techniques in general performed better than standard parametric models with smaller MSE irrespective of the data maturity. Survival outcomes projected by long-term extrapolation using immature data differed from those with mature data. Although a best-performing model was not found because several models had very similar MSE in this case, the variability of modeled ICERs significantly increased when prolonging simulation cycles. CONCLUSIONS: Flexible techniques show better performance in the case of Checkmate 067, regardless of data maturity. Model choices affect ICERs of cancer immunotherapy, especially when dealing with immature survival data. When researchers lack evidence to identify the ‘right’ model, we recommend identifying and revealing the model impacts on structural uncertainty. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-023-00391-5.
format Online
Article
Text
id pubmed-10169997
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-101699972023-05-11 Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067 Shao, Taihang Zhao, Mingye Liang, Leyi Shi, Lizheng Tang, Wenxi Pharmacoecon Open Original Research Article OBJECTIVES: The aim of this study was to compare the performance of different extrapolation modeling techniques and analyze their impact on structural uncertainties in the economic evaluations of cancer immunotherapy. METHODS: The individual patient data was reconstructed through published Checkmate 067 Kaplan Meier curves. Standard parametric models and six flexible techniques were tested, including fractional polynomial, restricted cubic splines, Royston–Parmar models, generalized additive models, parametric mixture models, and mixture cure models. Mean square errors (MSE) and bias from raw survival plots were used to test the model fitness and extrapolation performance. Variability of estimated incremental cost-effectiveness ratios (ICERs) from different models was used to inform the structural uncertainty in economic evaluations. All indicators were analyzed and compared under cut-offs of 3 years and 6.5 years, respectively, to further discuss model impact under different data maturity. R Codes for reproducing this study can be found on GitHub. RESULTS: The flexible techniques in general performed better than standard parametric models with smaller MSE irrespective of the data maturity. Survival outcomes projected by long-term extrapolation using immature data differed from those with mature data. Although a best-performing model was not found because several models had very similar MSE in this case, the variability of modeled ICERs significantly increased when prolonging simulation cycles. CONCLUSIONS: Flexible techniques show better performance in the case of Checkmate 067, regardless of data maturity. Model choices affect ICERs of cancer immunotherapy, especially when dealing with immature survival data. When researchers lack evidence to identify the ‘right’ model, we recommend identifying and revealing the model impacts on structural uncertainty. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-023-00391-5. Springer International Publishing 2023-02-09 /pmc/articles/PMC10169997/ /pubmed/36757569 http://dx.doi.org/10.1007/s41669-023-00391-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Shao, Taihang
Zhao, Mingye
Liang, Leyi
Shi, Lizheng
Tang, Wenxi
Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067
title Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067
title_full Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067
title_fullStr Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067
title_full_unstemmed Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067
title_short Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067
title_sort impact of extrapolation model choices on the structural uncertainty in economic evaluations for cancer immunotherapy: a case study of checkmate 067
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169997/
https://www.ncbi.nlm.nih.gov/pubmed/36757569
http://dx.doi.org/10.1007/s41669-023-00391-5
work_keys_str_mv AT shaotaihang impactofextrapolationmodelchoicesonthestructuraluncertaintyineconomicevaluationsforcancerimmunotherapyacasestudyofcheckmate067
AT zhaomingye impactofextrapolationmodelchoicesonthestructuraluncertaintyineconomicevaluationsforcancerimmunotherapyacasestudyofcheckmate067
AT liangleyi impactofextrapolationmodelchoicesonthestructuraluncertaintyineconomicevaluationsforcancerimmunotherapyacasestudyofcheckmate067
AT shilizheng impactofextrapolationmodelchoicesonthestructuraluncertaintyineconomicevaluationsforcancerimmunotherapyacasestudyofcheckmate067
AT tangwenxi impactofextrapolationmodelchoicesonthestructuraluncertaintyineconomicevaluationsforcancerimmunotherapyacasestudyofcheckmate067